What are the opening hours?

Monday 9am - 5pm Wednesday 9am - 5pm Friday 9am - 5pm Saturday 9am - 5pm

Anil Bajnath, MD

Home
United States
Hanover, MD
Anil Bajnath, MD

Where Precision Medicine meets Longevity! Join our journey to better, longer living!

Follow for expert insights, biohacking tips, and multiomic breakthroughs that empower you to become the 'CEO of Your Health' and optimize your life.

04/24/2026

Your cholesterol level may not just be raising your cardiovascular risk. According to new research, it may be actively aging your immune cells — and driving liver disease in the process.

A study just published in Nature Aging (Salladay-Perez, Avila et al., 2026) makes a compelling and clinically important case that macrophages — the immune cells that serve as the liver's frontline defense — can enter a state of true, irreversible cellular senescence, and that when they do, they become a central engine of chronic inflammation and metabolic dysfunction.

This matters for anyone thinking about aging, metabolic liver disease, or the biology of inflammaging.

Here is what the research found. Using multi-omic profiling across mouse and human models, the authors identified a distinct population of p21⁺TREM2⁺ senescent macrophages that are biologically separate from ordinary activated immune cells. These cells are not simply inflamed. They are permanently arrested, secreting a harmful cocktail of inflammatory proteins — what scientists call the SASP — and they accumulate progressively in the aging liver.

In young mice, approximately 5% of liver macrophages were senescent. In aged mice, that figure reached 50%.
Two drivers were identified: DNA damage and, particularly relevant for metabolic medicine, excess cholesterol loading.

When macrophages were exposed to high levels of LDL cholesterol in the laboratory, they adopted the full senescent phenotype — including characteristic protein markers, inflammatory secretion, and cell-cycle arrest. This is a striking finding. It suggests that high circulating LDL is not only damaging to blood vessels — it may be directly inducing a pathological senescent state in tissue-resident immune cells.

The liver connection is critical. These senescent macrophages were enriched in the livers of mice with metabolic dysfunction-associated steatotic liver disease, and the same transcriptomic signature was found in TREM2⁺ scar-associated macrophages from human cirrhotic liver tissue. This is not a mouse-only phenomenon — it appears to be present and relevant in human metabolic liver disease.

Perhaps most striking is what happened when senescent macrophages were therapeutically targeted. Treatment with ABT-263, a senolytic drug that selectively induces death in senescent cells, cleared p21⁺ macrophages from aged livers and MASLD livers in mice. The effects were broad: reduced liver inflammation, reduced steatosis, lower systemic inflammatory cytokines, and a 30% restoration of hepatic NAD⁺ levels — a molecule central to cellular energy metabolism that declines with aging.

For those of us thinking about chronic disease through a functional and precision medicine lens, this paper opens a significant new line of inquiry. Dietary cholesterol excess, microglial and macrophage activation, NAD⁺ decline, and inflammaging are not separate problems. They may be connected through a single cellular mechanism — macrophage senescence — that is now measurable, biologically distinct, and therapeutically targetable.

The implication is not just academic. If senescent macrophage accumulation in the liver is a modifiable driver of MASLD progression and systemic inflammaging, it warrants serious clinical attention — both in terms of how we manage metabolic risk and how we think about senolytic strategies in the context of aging and liver disease.

This paper is worth reading in full.

Salladay-Perez, Avila et al., Nature Aging, April 2026
https://doi.org/10.1038/s43587-026-01101-6

04/23/2026

What if measuring your biological age once is not enough — and what really matters is how fast it is changing?

That is the central question a remarkable new study just answered, and the implications reach well beyond academic research into the heart of how we practice longevity and precision medicine.

Published in Nature Aging (Kuo, Moore et al., 2026), this study followed 699 adults for up to 24 years — one of the longest epigenetic aging studies ever conducted in humans. Researchers measured DNA methylation at multiple timepoints and tracked seven different epigenetic clocks, spanning three generations of increasingly sophisticated biological age tools. They then asked whether the rate of change in those clocks predicted mortality, above and beyond a single baseline measurement.
It did. Significantly.

This finding reframes the entire conversation about epigenetic testing. Right now, most clinical epigenetic age assessments give you a number — your biological age, your pace of aging, your acceleration relative to chronological age. That number has real predictive value. But this study shows it is only part of the picture.
The direction and speed of biological aging over time carries independent information about mortality risk — information that no single measurement, however sophisticated, can provide. When both the baseline epigenetic age and the longitudinal trajectory were included together in the same predictive model, mortality prediction improved substantially, with concordance indices reaching as high as 0.808 across a 24-year follow-up.

That is a level of predictive performance that demands clinical attention.

Equally important is what this tells us about intervention monitoring. If epigenetic clocks can detect meaningful changes in the pace of biological aging — changes driven by lifestyle, environment, medication, or targeted longevity interventions — then serial measurement is not just a research tool. It becomes a clinical instrument. A way to know whether what we are doing is actually working at the molecular level, in real time, in living people.
The study also identified that second-generation clocks — specifically DNAmPhenoAge and DNAmGrimAge — performed best for mortality reclassification, while the third-generation DunedinPACE showed a particularly important pattern: its rate of acceleration increased as participants aged. This compounding effect means that the window for early intervention may be considerably more important than we have previously appreciated. Intervening earlier, when the pace of aging is still modifiable, is not just preferable — based on this data, it may be decisive.

For those of us working at the intersection of functional medicine, precision health, and longevity science, this paper does something important. It validates the biological meaningfulness of repeated epigenetic measurement. It gives us a scientific foundation for tracking aging trajectories over time rather than treating biological age as a single fixed data point. And it reinforces the geroscience hypothesis that the pace of biological aging — not just its current position — is the lever most worth pulling.

We are moving from biological age as a snapshot to biological age as a living, trackable trajectory. This study is one of the clearest demonstrations yet of why that shift matters.

It is worth reading in full.

Kuo, Moore et al., Nature Aging, March 2026
https://doi.org/10.1038/s43587-026-01066-6

04/22/2026

What if the immune system is trying to tell us about Alzheimer's disease years before diagnosis — and we just haven't been listening carefully enough?

That's the question this new research forces us to confront.
A study just published in Nature Aging (Blujdea et al., 2026) examined cerebrospinal fluid from 834 individuals across the full Alzheimer's continuum — from cognitively normal individuals all the way through preclinical disease to full dementia. The focus was not amyloid. Not tau. It was microglia — the brain's resident immune cells — and the protein signals they leave behind in spinal fluid long before a diagnosis is ever made.

The findings are difficult to ignore.
The brain's immune system activates early. Very early.
In individuals who were cognitively intact but already showing positive Alzheimer's biomarkers in their CSF — what researchers call preclinical AD — a distinct set of microglial proteins was already elevated. These proteins are linked to innate immune activation, cellular recruitment, and enhanced surveillance. The brain, it appears, is not passively waiting for disease to declare itself. It is mounting a response — organized, measurable, and detectable in spinal fluid — before a single cognitive symptom emerges.

This is not a minor finding. It fundamentally repositions neuroinflammation from a downstream consequence of Alzheimer's pathology to an early, active biological process that may be stageable and — critically — modifiable.
The immune landscape shifts as disease advances.

By the time patients reach the dementia stage, the proteomic picture looks entirely different. Proinflammatory chemokines — including CCL2, CXCL8, and CCL8 — rise sharply. Meanwhile, proteins associated with immune regulation and cellular communication decline. What begins as a potentially protective microglial response appears to transition, over time, into chronic immune dysregulation — one that may actively accelerate neurodegeneration rather than contain it.

93 proteins were dysregulated across both the preclinical and dementia stages simultaneously — suggesting that microgliosis in Alzheimer's disease is not a brief, episodic event but a sustained, evolving biological process that spans the entire disease course.
A protein panel that can stage the disease.

Perhaps the most clinically compelling result: an 18-protein CSF panel distinguished preclinical from dementia-stage Alzheimer's with an area under the curve of 0.94 in the discovery cohort and 0.88 in an independent replication cohort.

That is a level of discriminative performance that puts microglia-based biomarkers squarely in the conversation for clinical staging tools — not just research endpoints.

What this means in practice.
For those of us thinking about brain health through a functional and precision medicine lens, this research reinforces something we have long suspected: the inflammatory milieu of the brain is not static, it is not incidental, and it is not beyond our reach to measure. The therapeutic window in Alzheimer's disease may be considerably wider than standard clinical models assume — but only if we are looking at the right biology, at the right time.

Waiting for cognitive symptoms to appear before assessing neuroinflammatory burden may mean intervening a decade too late.

The conversation about Alzheimer's prevention and early intervention needs to include microglia. This paper makes that case with rigor, scale, and clinical precision.
It is worth reading in full.

Blujdea et al., Nature Aging, March 2026

https://doi.org/10.1038/s43587-026-01088-0

04/21/2026

One of the most counterintuitive findings in cancer biology: the cancer cells that are most resistant to chemotherapy may be the most vulnerable to a completely different kind of cell death.

A 2026 review in Trends in Cell Biology from researchers at Columbia University and Memorial Sloan Kettering Cancer Center details this paradox through the lens of ferroptosis — a form of cell death triggered by iron-dependent peroxidation of fatty acids in cell membranes.

Here is why this matters: cancer cells, in order to grow rapidly, accumulate high levels of iron and reactive oxygen species. This makes them inherently more vulnerable to ferroptosis than normal cells. More strikingly, drug-resistant cancer cells in a mesenchymal state — the kind that survive chemotherapy and radiation — show higher ferroptosis sensitivity, not lower. Cancer stem cells are similarly vulnerable.

But cancers also evolve resistance to ferroptosis through multiple pathways: upregulating antioxidant enzymes like GPX4 and FSP1, shifting their membrane lipids toward ferroptosis-resistant monounsaturated fats, and exploiting the tumor microenvironment's hypoxia and acidity to suppress iron-dependent cell death.

The key insight from this review is that effective ferroptosis-based therapy requires a two-component approach: a ferroptosis inducer combined with a ferroptosis-priming agent that targets the specific resistance mechanism of a given tumor. Some tumors rely on FSP1, others on SCD1-mediated lipid remodeling, others on the hormone receptor pathway — and each can be targeted accordingly.

Several ferroptosis inducers are already in preclinical development, and two FDA-approved drugs — sorafenib and sulfasalazine — cause some degree of ferroptotic cell death as part of their mechanism of action.

This is a field moving rapidly toward clinical translation.

https://doi.org/10.1016/j.tcb.2026.03.008

04/20/2026

What if removing two amino acids from the diet could force cancer cells to stop growing and mature into normal-like cells?

A commentary just published in the New England Journal of Medicine discusses precisely this — in the context of one of the deadliest childhood cancers.

MYCN-amplified neuroblastoma is highly aggressive and difficult to treat. It depends on polyamines — small molecules essential for cell proliferation. Researchers found that combining an arginine- and proline-free diet with eflornithine, a drug that blocks polyamine synthesis, created a "double hit" that starved tumors of the ornithine they need to make polyamines.

The dietary intervention depleted systemic ornithine, while the drug blocked the conversion of any remaining ornithine into polyamines.
What happened next was unexpected. The resulting drop in spermidine impaired a critical translation factor called eIF5A. This caused ribosomes — the cell's protein-making machinery — to stall specifically at codons enriched in cell-cycle and proliferation genes, while genes driving neural differentiation continued to be translated normally.

The proteome shifted, and tumor cells began differentiating into more mature neurons rather than continuing to divide. Two thirds of treated tumors in the mouse model showed signs of differentiation.

The authors note that codon use appears to have been evolutionarily encoded so that metabolic states — like polyamine abundance — can simultaneously regulate entire gene programs. A metabolic switch, written into the genome.

This is early-stage, preclinical work, and the authors are clear that adequately powered clinical trials are the necessary next step. But as a proof of concept that diet can reprogram cancer biology at the molecular level, this is worth reading.

https://doi.org/10.1056/NEJMcibr2516825

04/17/2026

What if one of the most powerful predictors of survival after a bone marrow transplant is the state of the patient's gut bacteria?

A major 2026 review in Nature Reviews Cancer from researchers at City of Hope makes exactly this case. In allogeneic haematopoietic cell transplantation — a potentially curative treatment for blood cancers — graft-versus-host disease (GVHD) remains a leading cause of death, affecting 35–46% of patients within 6 months and proving resistant to first- and second-line therapies in a substantial proportion of cases.

The review synthesizes years of preclinical and clinical research demonstrating that the intestinal microbiome is a major, non-genetic regulator of GVHD severity. Loss of microbial diversity — driven by chemotherapy, broad-spectrum antibiotics, dietary changes, and the transplant process itself — depletes protective bacteria that produce butyrate, secondary bile acids, and tryptophan metabolites. These metabolites are critical for maintaining gut barrier integrity and suppressing alloreactive T cell responses. When they disappear, GVHD accelerates.

Importantly, the review highlights that recipient microbiota can shape donor T cell responses independently of genetic donor-recipient mismatch — fundamentally reframing how we understand GVHD causation. On the therapeutic side, approaches ranging from dietary modification and antibiotic stewardship to FMT and standardized microbiota consortia products are now in clinical trials, with the phase III ARES trial of MaaT013 meeting its primary endpoint in ruxolitinib-refractory gastrointestinal aGVHD.

This review makes a compelling case for integrating microbiome profiling into transplant risk stratification and treatment decision-making.

https://doi.org/10.1038/s41568-026-00910-6

04/16/2026

Why are younger adults getting cancer at rising rates — and what can we do about it?

A 2026 perspective published in Cell by researchers from Washington University, Yale, and the WHO's International Agency for Research on Cancer confronts one of the most urgent trends in modern oncology: the global rise of early-onset cancers in adults under 50, with particularly strong birth-cohort effects in Generation X and Millennials.

The authors argue that our current frameworks for identifying cancer causes are inadequate for this challenge. Most epidemiologic cohorts begin in midlife, health records rarely capture childhood exposures, and emerging factors like circadian disruption, ultra-processed foods, and environmental chemicals are seldom measured longitudinally. As a result, the first decades of life — precisely when many cancer-promoting biological imprints are laid down — remain largely invisible to researchers.

Their proposed solution is a shift toward tissue ecosystem-level thinking: understanding how cumulative exposures across the life course leave durable epigenetic, immune, metabolic, and microbial signatures that shape cancer susceptibility long before a diagnosis is ever made. They also call for dynamic, biology-informed risk models that update over time, and prevention frameworks anchored in cancer's natural history rather than static population averages.

This is a foundational paper for anyone thinking seriously about the future of cancer prevention.

https://doi.org/10.1016/j.cell.2026.03.019

04/15/2026

What if the reason cancer therapies fail isn't resistance — but the wrong metabolic target, in the wrong tumor, at the wrong time?

A 2025 review in Cell Reports from Yale School of Medicine examines how amino acid metabolism in cancer is not uniform — it varies between tumor types, between patients, and even between regions within the same tumor. The authors systematically cover glutamine, asparagine, aspartate, serine, methionine, cysteine, arginine, BCAAs, tyrosine, and tryptophan, demonstrating that each pathway is shaped by tissue of origin, oncogenic drivers, and the tumor microenvironment.

One striking finding: inhibiting glutaminase systemically can actually harm anti-tumor immunity by starving CD8+ T cells of glutamate — the opposite of the intended effect. Meanwhile, broader glutamine blockade enhanced immunotherapy response in lung cancer and brain tumors.

This review makes a compelling case for metabolic precision medicine — profiling the specific amino acid dependencies of a patient's tumor before selecting a therapeutic strategy.
Worth reading for any clinician or researcher working at the intersection of oncology and metabolism.

https://doi.org/10.1016/j.celrep.2025.115529

04/14/2026

What if the conditions surrounding your child's birth shaped their brain development — at the level of their DNA?

A 2026 longitudinal study from The Chinese University of Hong Kong followed 969 families from pregnancy through age 3, analyzing cord blood epigenomes and serial gut microbiome samples. Researchers found that Caesarean delivery was associated with widespread hypermethylation of genes governing neural development and neurotransmission.

Children with higher methylation of these genes had elevated ASD and ADHD scores by age 3.

What's remarkable: specific early-life gut bacteria — Lachnospira pectinoschiza and Parabacteroides distasonis — partially mitigated these epigenetic risks, mediating roughly 8% of the effect on neurodevelopmental scores.

This is among the first studies to map the epigenome-microbiome-neurodevelopment axis in humans, longitudinally, at scale. The findings point toward early microbial intervention as a plausible strategy for neurodevelopmental risk reduction.

Worth reading in full.
https://doi.org/10.1016/j.cpblue.2026.100009

04/13/2026

Why do cells lose their identity as we age? And why do the same anti-ageing interventions — partial reprogramming, chemical cocktails, chromatin-modifying therapies — consistently work across different tissues and disease contexts?

A landmark 2026 review from Harvard Medical School published in Nature Reviews Molecular Cell Biology provides the most mechanistically integrated answer to date.

Ageing, the authors argue, is not simply a random accumulation of epigenetic errors. It is a systems-level failure of chromatin's capacity to maintain cell identity — driven by four interconnected processes: the breakdown of genome architecture, the collapse of Polycomb-mediated regulatory memory, the progressive replacement of canonical histones by the variant H3.3, and the hostile takeover of gene regulatory elements by the stress-responsive transcription factor AP-1.

What makes this framework clinically important is its therapeutic clarity. The same chromatin circuit that fails during ageing can be restabilized — and cyclic expression of a single transcription factor, FOXM1, has already extended mouse median lifespan by 29% by repressing AP-1 activity and restoring youthful chromatin profiles.

For physicians and researchers in precision and functional medicine, this review maps the molecular architecture of ageing at a resolution that makes rational therapeutic design possible — not someday, but now.

📄 https://doi.org/10.1038/s41580-026-00958-0
Yücel & Gladyshev, Nature Reviews Molecular Cell Biology, March 2026

04/10/2026

One in eight Americans has now used a GLP-1 medication. Yet response varies enormously — some patients lose 25% of their body weight, others lose less than 5%. A landmark 2026 study published in Nature now explains part of why: your genes.

Researchers at 23andMe analyzed genomic data from nearly 28,000 GLP-1 medication users and identified specific variants in the receptor genes that these drugs target. A variant in GLP1R predicts meaningfully greater weight loss. A separate variant in GIPR — specific to tirzepatide users — dramatically increases the risk of vomiting, with the highest-risk patients carrying a nearly 15-fold increased likelihood of experiencing this side effect.

The study also finds that nausea and vomiting are not simply unwanted complications — they appear to share a common genetic basis with efficacy, suggesting that some of the discomfort patients experience may be biologically linked to the drug's mechanism of action.

For physicians practicing precision and functional medicine, this study provides a concrete, evidence-based foundation for genotype-guided drug selection and dose escalation in GLP-1 therapy — potentially improving outcomes and reducing unnecessary side effects from the outset of treatment.

📄 https://doi.org/10.1038/s41586-026-10330-z

Su, Ashenhurst, Auton et al., Nature, April 2026

04/08/2026

We have long known that environment shapes health. This 2026 study in Nature Medicine now quantifies precisely how much it shapes brain aging — and the answer is more substantial than most clinical frameworks currently account for.

Across 18,701 participants from 34 countries, researchers mapped 73 physical and social exposomal factors — including air pollution, access to green space, extreme precipitation, poverty, political instability, and gender inequality — against multimodal brain age clocks. The combined exposome explained up to 15.5 times more variance in brain aging than any single factor. Exposome burden increased the risk of accelerated brain aging by 3.3 to 9.1 times — surpassing the risk attributed to clinical diagnoses including Alzheimer's disease.

For physicians and researchers working in precision and functional medicine, this is a critical signal: addressing brain aging requires moving beyond pharmaceuticals and diagnostics toward the structural environmental and sociopolitical determinants that drive biological aging at scale.

📄 https://doi.org/10.1038/s41591-026-04302-z

Legaz, Moguilner, Ibanez et al., Nature Medicine, 2026

Address

7030 Hi Tech Drive Suite 101
Hanover, MD
21076

Opening Hours

Monday	9am - 5pm
Wednesday	9am - 5pm
Friday	9am - 5pm
Saturday	9am - 5pm

Website

https://anilbajnath.com/

Alerts

Be the first to know and let us send you an email when Anil Bajnath, MD posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Anil Bajnath, MD:

Shortcuts

Want your practice to be the top-listed Clinic in Hanover?

About Dr. Bajnath’s

Dr. Bajnath’s primary field of interest is understanding the underlying causes of unresolved illness and formulating care plans for resolving these complex medical scenarios. He also actively researches pharmacogenomics, nutrigenomics and the microbiome sciences.

Dr. Bajnath completed his undergraduate studies in Molecular-cellular Microbiology (MM) and Medical Laboratory Sciences (MLS) at the University of Central Florida. He graduated medical school with honors from Ross University School of Medicine and additionally was a recipient of a scholarship from Keller School of Business Administration for a Master in Business Administration (MBA) with a focus in Healthcare Services. He completed his residency training with the University of Maryland Department of Family and Community Medicine in January 2019. During his medical school training, Dr. Bajnath assisted and published research with Cleveland Clinic Hospital department of Nephrology. In addition to his conventional training Dr. Bajnath pursued additional training in the field of healing sciences. He completed an extensive seminar series in European Biological Medicine with Paracelsus Clinic of Biological medicine and completed a fellowship and obtained master level instructor status with the Institute for Human Individuality (MIfHI) an organization which professed the concepts of nutrigenomic systems biology and network medicine. He is also a Institute for Functional Medicine Certified Practicioner (IFMCP) and is Board Certified in Anti-Aging and Regenerative Medicine (ABAARM). Additionally, Dr. Bajnath has completed training in integrative medicine which included Clinical Nutrition, Medical Acupuncture, Herbal Medicine, Clinical Homeopathy.

Dr. Bajnath has an extensive history of utilizing complementary alternative medicine techniques to treat his patients. He is a formative expert in helping patients employ prescriptive practices and nutritional modifications based on genomics, exercise and wellness programs into their daily routines in order to better manage their health. In his practice, Dr. Bajnath is committed to formulating an accurate diagnosis and specific care plan for each of his patients. To aid him in this effort, he uses a thorough initial lab evaluation and genomic analysis to quickly uncover the deeper, underlying problems that lead to illness or disease.